GLP-1 Receptor Agonists: A Class Overview

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Welcome to the PlexusDx Education Hub, where we translate GLP-1 science, weight-management options, and the genetic signals underneath them into plain language. Browse the full Peptides & GLP-1 library.

The plural in "GLP-1 receptor agonists" is a clue: this search is usually about the whole family and how its members compare, not a single product. So this overview maps the class as a set — the shared mechanism that unites them, the ways they diverge, the formats they come in, and the genetic backdrop that applies to all of them at once.

The common thread across the class

Every agent here activates the GLP-1 receptor, the docking site for glucagon-like peptide-1, an incretin hormone released by intestinal L-cells after meals. Activation produces a consistent set of effects across the family: glucose-dependent insulin secretion, glucagon suppression, slowed gastric emptying, and hypothalamic satiety signaling. That shared mechanism is what lets us treat these otherwise different molecules as a single class.

How the members diverge

Within that common mechanism, the agents differ in meaningful ways. The natural hormone survives only about two minutes before DPP-4 clears it, so each drug is engineered for DPP-4 resistance, but the resulting half-lives — and therefore dosing schedules — vary from daily to weekly. Receptor targeting differs too: most engage GLP-1 alone, while tirzepatide-based compounds also activate the GIP receptor, a defining distinction in the class as of April 2026.

The roster, agent by agent

FDA-approved members as of April 2026 include exenatide (Byetta in 2005, Bydureon), liraglutide (Victoza in 2010, Saxenda in 2014), dulaglutide (Trulicity in 2014), semaglutide (Ozempic in 2017, Rybelsus in 2019, Wegovy in 2021), and tirzepatide (Mounjaro in 2022, Zepbound in 2023, extended to obstructive sleep apnea in 2024). Beyond the approved set, retatrutide — a triple agonist adding the glucagon receptor — and orforglipron, an oral non-peptide small molecule, are in late-stage development but not approved.

Formats and how they are taken

As a group, most of these agonists are subcutaneous injections given weekly or, for a few, daily. Rybelsus is the lone FDA-approved oral tablet as of April 2026. Compounded formulations are available through licensed 503A compounding pharmacies via regulated pathways; those are not FDA-approved branded products and differ legally from the reference medicines.

The genetic backdrop shared by the whole family

Because the entire class acts on one receptor pathway, a single set of genes describes the terrain for all of them. FTO shapes appetite and adiposity set-point, GLP1R influences receptor density and signaling, MC4R tunes satiety, and TCF7L2 affects insulin secretion and incretin response. The PlexusDx Precision Peptide Genetic Test reads 14 pathways, 49 peptides, 150+ genetic insights across these traits — educational trait mapping, never a pharmacogenomic prediction of drug response. Reviewed with the Weight Management Protocols, it frames the upstream biology every member of the class shares.

More on PlexusDx: What Is GLP-1? and GLP-1 Hormone.

Reading the family as a spectrum

The most useful way to hold this class in your head is as a spectrum rather than a pile of brand names. At one end sit the single-target agonists that execute the core mechanism; in the middle sits the dual agonist that adds GIP activity; at the investigational edge sits the triple agonist reaching for a third receptor. Format runs as a second axis, from the many weekly injections to the single approved oral tablet, with compounded formulations occupying their own regulated lane.

Placed on that map, any specific agent becomes easy to locate, and the differences that matter — dosing frequency, receptor targeting, approved indication, delivery route — come into focus without memorization. It also clarifies why one shared set of genes describes the whole family: the mechanism they have in common is precisely the mechanism your inherited biology varies around, which is the upstream context every member of the class ultimately answers to.

Frequently Asked Questions

How many GLP-1 receptor agonists are FDA-approved?

As of April 2026 the approved molecules include exenatide, liraglutide, dulaglutide, semaglutide, and the GIP/GLP-1 dual agonist tirzepatide, each marketed under multiple brand names for different indications. Retatrutide and orforglipron are still investigational, so the exact count depends on whether you tally molecules or individual branded products.

What separates one agonist from another?

They differ in half-life and dosing frequency, receptor targeting — GLP-1 alone versus dual GLP-1/GIP — format, and approved indications. Some are approved for type 2 diabetes, others additionally for chronic weight management, cardiovascular risk reduction, or obstructive sleep apnea. Your prescriber matches a specific agent to a specific labeled use.

Are the injectable and oral agonists interchangeable?

Not automatically. They differ in molecule, absorption, and dosing requirements, and Rybelsus is currently the only FDA-approved oral option. Switching between formats or agents is a clinical decision that accounts for indication, tolerability, and individual factors, so it belongs in a conversation with a qualified healthcare provider.

Does genetic testing rank the agonists for me?

No. The Precision Peptide Genetic Test does not rank or predict response to any agent in the class. It reads pathway-level variants in FTO, GLP1R, MC4R, and TCF7L2 that describe your baseline metabolic and appetite biology — shared upstream context for the class, offered to inform a provider discussion rather than to choose a drug.

Keep exploring inside the PlexusDx Education Hub. Return to all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.